Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Increase in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, a growth of 1,012.9% from the December 31st total of 187,800 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average trading volume of 6,360,000 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on APTO. StockNews.com assumed coverage on Aptose Biosciences in a report on Friday, January 24th. They set a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a report on Friday, January 10th.

Aptose Biosciences Trading Down 5.7 %

Shares of APTO opened at $0.19 on Wednesday. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.20. The firm has a fifty day simple moving average of $0.21 and a 200 day simple moving average of $0.36. The stock has a market capitalization of $11.54 million, a price-to-earnings ratio of -0.06 and a beta of 0.87.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.